A citation-based method for searching scientific literature

Yumo Zhao, Lubin Xu, Dongli Tian, Peng Xia, Hua Zheng, Li Wang, Limeng Chen. Diabetes Obes Metab 2018
Times Cited: 107



Laween Uthman, Antonius Baartscheer, Boris Bleijlevens, Cees A Schumacher, Jan W T Fiolet, Anneke Koeman, Milena Jancev, Markus W Hollmann, Nina C Weber, Ruben Coronel, Coert J Zuurbier. Diabetologia 2018
Times Cited: 190




List of shared articles



Times cited

Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPA-HF Study Population: A Mathematical Modeling Analysis.
Hongtao Yu, Weifeng Tang, Peter J Greasley, Robert C Penland, David W Boulton, K Melissa Hallow. J Clin Pharmacol 2021
3

SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms.
Maja Nikolic, Vladimir Zivkovic, Jovana Joksimovic Jovic, Jasmina Sretenovic, Goran Davidovic, Stefan Simovic, Danijela Djokovic, Nemanja Muric, Sergey Bolevich, Vladimir Jakovljevic. Heart Fail Rev 2021
6


Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects.
Giuseppe Palmiero, Arturo Cesaro, Erica Vetrano, Pia Clara Pafundi, Raffaele Galiero, Alfredo Caturano, Elisabetta Moscarella, Felice Gragnano, Teresa Salvatore, Luca Rinaldi,[...]. Int J Mol Sci 2021
3

Uric acid as a cardiorenal mediator: pathogenesis and mechanistic insights.
Asma Gulab, Ricardo Torres, Jerald Pelayo, Kevin Bryan Lo, Anum Shahzad, Supriya Pradhan, Janani Rangaswami. Expert Rev Cardiovasc Ther 2021
0

Sodium-Glucose Co-transporter-2 Inhibitors and Nephroprotection in Diabetic Patients: More Than a Challenge.
Michele Provenzano, Maria Chiara Pelle, Isabella Zaffina, Bruno Tassone, Roberta Pujia, Marco Ricchio, Raffaele Serra, Angela Sciacqua, Ashour Michael, Michele Andreucci,[...]. Front Med (Lausanne) 2021
0

Diabetes, Heart Failure and Beyond: Elucidating the Cardioprotective Mechanisms of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors.
Utkarsh Ojha, Lenisse Reyes, Florence Eyenga, Diane Oumbe, Justyna Watkowska, Henock Saint-Jacques. Am J Cardiovasc Drugs 2021
2

Sodium-Glucose Cotransporter-2 Inhibitors in Vascular Biology: Cellular and Molecular Mechanisms.
Lei Xiao, Xin Nie, Yanyan Cheng, Nanping Wang. Cardiovasc Drugs Ther 2021
1

SGLT2 Inhibitors and Their Mode of Action in Heart Failure-Has the Mystery Been Unravelled?
Steffen Pabel, Nazha Hamdani, Mark Luedde, Samuel Sossalla. Curr Heart Fail Rep 2021
0

SGLT2 inhibitors in heart failure with reduced ejection fraction.
Uday Sankar Das, Aritra Paul, Suvro Banerjee. Egypt Heart J 2021
0

Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence.
Benedetta Maria Bonora, Angelo Avogaro, Gian Paolo Fadini. Diabetes Metab Syndr Obes 2020
30


Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology.
Petar M Seferović, Gabriele Fragasso, Mark Petrie, Wilfried Mullens, Roberto Ferrari, Thomas Thum, Johann Bauersachs, Stefan D Anker, Robin Ray, Yuksel Çavuşoğlu,[...]. Eur J Heart Fail 2020
36



Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes-cardiovascular and renal benefits in patients with chronic kidney disease.
Tamara Y Milder, Sophie L Stocker, Dorit Samocha-Bonet, Richard O Day, Jerry R Greenfield. Eur J Clin Pharmacol 2019
3